4 Merger and Acquisitions Stock Stories for Wednesday Appraisal

Verizon Communications (NYSE:VZ): Current price $48.01

In a Tuesday U.S. Securities and Exchange Commission Exhibit 99 form, the company stated, “Verizon Communications Inc. notes the recent press speculation regarding a potential merger with or purchase by Verizon of Vodafone. As Verizon has said many times, it would be a willing purchaser of the 45 percent stake that Vodafone holds in Verizon Wireless. It does not, however, currently have any intention to merge with or make an offer for Vodafone, whether alone or in conjunction with others.”

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

vz

Starbucks (NASDAQ:SBUX): Current price $58.16

Starbucks’ partner in Mexico, Alsea, said Tuesday that it has purchased sole ownership of Starbucks’ coffee business in there, with intentions to launch 50 stores per year for the next five years. The acquisition was financed with bank loans and the purchase price was not divulged. Alsea Chief Executive Fabian Gosselin commented in a release, “Obtaining 100 percent of the business in Mexico will allow us to extend the contract’s exclusivity, add profitability and value to Alsea’s consolidated results and thus obtain a better return on our investment.”

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

sbux

Rosetta Stone (NYSE:RST): Current price $15.77

Rosetta Stone has purchased Livemocha, an online language-learning community, in a cash transaction of $8.5 million. Featuring a robust and extensible cloud-based learning platform and a community in excess of 16 million Livemocha members, the acquisition steps ups Rosetta Stone’s transition to cloud-based learning solutions.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

rstBiogen IDEC (NASDAQ: BIIB) Current price $194.88

The firm announced Tuesday that it has finalized its purchase of Elan Corporation’s interest in Tysabri (natalizumab) and has gained full strategic, commercial and decision-making rights to the drug. The transaction was originally reported on February 6. Chief Executiveeorge A. Scangos, Ph.D. said that “full ownership of Tysabri is an important step for Biogen Idec that further solidifies our leadership in MS.”

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

biib

Investing Insights: Can Boeing’s Stock Fly Higher?

More Articles About:   , ,  

More from The Cheat Sheet